Documente Academic
Documente Profesional
Documente Cultură
during ARDS
SRLF 1st International Conference
Paris - June 9th, 2011
Claude Guérin
Réanimation Médicale
Hôpital de la Croix Rousse
Université de Lyon
INSERM 630
Lyon, France
SRLF June
2011 1
Benefits from PP
Improvement of oxygenation
VILI prevention
Survival increase
VAP reduction
SRLF June 2
2011
1. Oxygenation
SRLF June
Gattinoni et al. NEJM 2001 3
2011
Oxygenation
Prone Supine
SRLF June 5
2011
Oxygenation
Improvement of oxygenation
No change in CO
Qs/QT
No change in FRC ?
1.2
0.8 SP
PP
0.4 Broccard et al.
0 CCM 2000
SRLF June ND D total 9
2011
16 normal rats per group
Pao *
Pes
EELV
SRLF June
VT/EELV 11
2011
Alveolar recruitment and reduction of hyperinflation
Right Lung
Left Lung
Alveolar recruitment
Decrease in hyperinflation
SRLF June
Galiastou AJRCCM 2006 14
2011
Cytokines production
SRLF June 15
2011
BAL cytokines (pg/ml)
IL-8 IL-1β
*
IL-6 TNF-α
SRLF June 17
2011
ALI/ARDS + PEEP ≥ 5 cm H2O Gattinoni et al. NEJM 2001
VT (ml/kg)
PEEP (cmH2O)
SRLF June 18
2011
Hypoxemic ARF P/F < 300
Guérin et al. JAMA 2004
VT (ml/kg)
PEEP (cmH2O)
SRLF June 19
2011
ARDS + 4 quadrants
on chest X Ray Mancebo et al. AJRCCM 2006
VT (ml/kg)
PEEP (cmH2O)
SRLF June 20
2011
ARDS + PEEP ≥ 5 cm H2O Taccone et al. JAMA 2009
SRLF June 21
2011
P/F < 100
P = 0.02
P = 0.03
RR reduction of 16%
SRLF June
Gattinoni et al. Minerva Anesthesiologica 2010 22
2011
Sud S. et al. Prone Ventilation Reduces Mortality in Patients with Acute Respiratory failure
and Severe Hypoxemia: Systematic Review and Meta-Analysis. ICM 2010
SRLF June 23
2011
severe moderate
SRLF June 25
2011
Prone position sessions’ duration
Abroug CC 2011
SRLF June 26
2011
Between 1997-2009
Primary end-point
Day 28 mortality from all causes
NIH study’s low VT arm in supine vs. in prone position
Proning for at least 16 hours/day
In selected patients with Severe and Persistent ARDS
P/F < 150 mmHg + FIO2 ≥ 60% + PEEP ≥ 5 cmH2O + VT 6 ml/Kg
IBW
ARDS criteria still present after 12-24 Hrs
Powering
Reduction of mortality from 60 to 45% by PP, α 5%, β 10%
230 patients per group
SRLF June 30
2011
Proseva trial is very close to its termination
456 patients (230 PP 226 SP) included since January 1st, 2008
SRLF June 31
2011
Summary
SRLF June 32
2011
I would like to thank
my colleagues (JC Richard, F Bayle, G Bourdin, V Leray,
SRLF June 33
2011